Seeking Alpha

Ben Yoffe

 
View as an RSS Feed
View Ben Yoffe's Comments BY TICKER:
Latest  |  Highest rated
  • MLV Sees A Good Chance Of FDA Approval For MannKind's Afrezza And 60% Upside [View article]
    adam feuerstein: "I'll say it now.... MNKD and its supporters were right about Afrezza approval. I was wrong. Still waiting for T2 vote but it will also be positive."

    Hope he learned something. Congrats!
    Apr 1 04:48 PM | 1 Like Like |Link to Comment
  • MLV Sees A Good Chance Of FDA Approval For MannKind's Afrezza And 60% Upside [View article]
    I understand the conflict, but regardless, I do believe Dr. Suvannavejh has some good arguments, which are worth to be considered, as well as Feuerstein. I think the interview makes the April 1 AdCom much more exciting, and we will see how it goes.
    Mar 18 07:21 PM | Likes Like |Link to Comment
  • IntelGenx Technologies: A Small Cap Company With The Potential For Significant Gains [View article]
    Good articles, but I believe that mostly all of your points are already baked into the stock price, at this point.
    Jan 29 08:01 AM | 1 Like Like |Link to Comment
  • Cowen Gives An Outlook On Auxilium's Future Following Peyronie's Approval [View article]
    Thanks, GUDoc. I appreciate your in-depth comments.
    Dec 21 12:49 PM | Likes Like |Link to Comment
  • Progenics: Investors Should Remain Cautious Heading Into The Relistor Panel [View article]
    The purpose is to give you information on which you can make a reasonable and informed decision on whether or not to invest in PGNX in the following months.
    Dec 10 12:29 PM | Likes Like |Link to Comment
  • Canaccord Genuity Sees Strong Upside In Venaxis' Shares And Set A $7 Price Target [View article]
    Thank you.
    Jun 27 06:30 AM | Likes Like |Link to Comment
  • Exclusive Interview With Stephen Lundy, Venaxis President And CEO [View article]
    Hi Stef34. We shall wait and see. However, it seems the company will be satisfied to achieve the same results as the previous 500-patient study, which was completed in 2011.
    Jun 27 05:31 AM | Likes Like |Link to Comment
  • Exclusive Interview With Stephen Lundy, Venaxis President And CEO [View article]
    Hi Norroway. Typical guidelines, I assume.
    Jun 27 05:20 AM | Likes Like |Link to Comment
  • Maxim Group Sees 350% Upside In Shares Of Omeros Corporation [View article]
    I guess time will tell. I'm planning to write a few more interviews regarding OMER in the next upcoming months. It will be interesting to watch.
    May 4 02:15 PM | 2 Likes Like |Link to Comment
  • Vivus Still Needs The Help Of A Big Pharma Partner, Say Cowen's Analysts [View article]
    Thanks for the kind words HT. You can send Spencer a private message.
    Feb 15 07:14 PM | Likes Like |Link to Comment
  • JMP Securities Sees 80% Chance Of FDA Approval For Raptor's RP103 [View article]
    Thank you for the kind words David.

    Cystagon is currently priced at about $9,000 per year.

    I think the drug will be approved, but , I'm not a buyer at the current price.
    Dec 31 11:21 AM | Likes Like |Link to Comment
  • Maxim Group Highlights 3 Stem Cell Stocks To Consider And 1 To Avoid [View article]
    Mr. Kolbert doesn't cover ACTC. However, Maxim has it in its "Spotlight" list.
    Dec 30 01:57 AM | Likes Like |Link to Comment
  • Maxim Group Highlights 3 Stem Cell Stocks To Consider And 1 To Avoid [View article]
    The closer we get to the truth, the louder you'll shout "ignorance!".
    Dec 5 08:43 PM | Likes Like |Link to Comment
  • JMP Securities Sees 80% Chance Of FDA Approval For Raptor's RP103 [View article]
    If you had bought RPTP on the day this article was published, you could sell it for 25% higher, two months later. The stock is at the same level now as it was when it was published.
    Nov 11 06:28 AM | Likes Like |Link to Comment
  • WBB Securities Recommends Alexza Pharmaceuticals As A Strong Buy [View article]
    Up 45% today.
    Aug 13 01:31 PM | Likes Like |Link to Comment
COMMENTS STATS
39 Comments
6 Likes